Crestwood Advisors Group’s Cidara Therapeutics CDTX Stock Holding History

Crestwood Advisors Group’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,683	Closed	-$1.7M	–	774
2025 Q4	$1.7M	Buy	+7,683	New	+$1.24M	0.03%	227

Crestwood Advisors Group's CDTX Position: Q1 2026 in Review

Crestwood Advisors Group sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 7,683 shares — an estimated $1.7M sold.

Crestwood Advisors Group first reported a position in CDTX in Q4 2025 and held it in 1 quarter. The position peaked at $1.7M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Crestwood Advisors Group reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Crestwood Advisors Group sold 7,683 Cidara Therapeutics shares in Q1 2026, an estimated $1.7M.
Crestwood Advisors Group first reported a position in Cidara Therapeutics in Q4 2025 and held it in 1 quarter.
Crestwood Advisors Group's Cidara Therapeutics position peaked at $1.7M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Crestwood Advisors Group's 13F filing for Q1 2026, filed 5 May 2026.